<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> increases the risk of microvascular events </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is continuing uncertainty about its effect on macrovascular outcomes and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a meta-analysis of prospective studies to estimate the association of glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level with the risk of <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and cardiovascular outcomes among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODOLOGY/PRINCIPAL FINDINGS: We systematically searched the MEDLINE database through April 2011 by using Medical Subject Heading search terms and a standardized protocol </plain></SENT>
<SENT sid="4" pm="."><plain>We included prospective cohort studies that reported data of glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level on the risk of incident cardiovascular events and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="5" pm="."><plain>Relative risk estimates (continuous and categorical variables) were derived or abstracted from each cohort study </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty six studies were included in this analysis with a mean follow-up rang of 2.2-16 years </plain></SENT>
<SENT sid="7" pm="."><plain>The pooled relative risk associated with a 1% increase in glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was 1.15 (95% CI, 1.11 to 1.20) for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, 1.17 (95% CI, 1.12 to 1.23) for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, 1.15 (95% CI, 1.10 to 1.20) for <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, 1.11 (95% CI, 1.05 to 1.18) for <z:hpo ids='HP_0001635'>heart failure</z:hpo>, 1.11 (95% CI, 1.06 to 1.17) for <z:hpo ids='HP_0001297'>stroke</z:hpo>, and 1.29 (95% CI, 1.18 to 1.40) for <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, a positive dose-response trend existed between glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level and cardiovascular outcomes </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/SIGNIFICANCE: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> is associated with an increased risk for cardiovascular outcomes and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, likely independently from other conventional risk factors </plain></SENT>
</text></document>